CNGLX
Price
$20.30
Change
-$0.56 (-2.68%)
Updated
Dec 18 closing price
RWIBX
Price
$62.66
Change
-$1.77 (-2.75%)
Updated
Dec 18 closing price
Ad is loading...

CNGLX vs RWIBX

Header iconCNGLX vs RWIBX Comparison
Open Charts CNGLX vs RWIBXBanner chart's image
Commonwealth Global
Price$20.30
Change-$0.56 (-2.68%)
VolumeN/A
CapitalizationN/A
American Funds Capital World Gr&Inc R2
Price$62.66
Change-$1.77 (-2.75%)
VolumeN/A
CapitalizationN/A
CNGLX vs RWIBX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CNGLX vs. RWIBX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CNGLX is a StrongBuy and RWIBX is a Buy.

FUNDAMENTALS
Fundamentals
RWIBX has more cash in the bank: 121B vs. CNGLX (17.4M). RWIBX pays higher dividends than CNGLX: RWIBX (1.05) vs CNGLX (0.00). CNGLX was incepted earlier than RWIBX: CNGLX (22 years) vs RWIBX (23 years). RWIBX is a more actively managed with annual turnover of: 27.00 vs. CNGLX (9.00). CNGLX has a lower initial minimum investment than RWIBX: CNGLX (200) vs RWIBX (250). RWIBX annual gain was more profitable for investors over the last year : 11.34 vs. CNGLX (8.93). RWIBX return over 5 years is better than : 29.64 vs. CNGLX (25.51).
CNGLXRWIBXCNGLX / RWIBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence22 years23 years-
Gain YTD7.1399.78173%
Front LoadN/AN/A-
Min. Initial Investment20025080%
Min. Initial Investment IRAN/AN/A-
Net Assets17.4M121B0%
Annual Yield % from dividends0.001.05-
Returns for 1 year8.9311.3479%
Returns for 3 years-0.818.41-10%
Returns for 5 years25.5129.6486%
Returns for 10 years36.8844.2283%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LITM0.180.03
+17.46%
Snow Lake Resources Ltd
NUVB2.810.12
+4.46%
Nuvation Bio
ENTG109.362.65
+2.48%
Entegris
ARQ7.01-0.04
-0.57%
Arq
PTCT47.02-1.59
-3.27%
PTC Therapeutics